Cargando…

Patient Factors in the Dose Selection of Oral Sumatriptan for Acute Migraine: A Post Hoc Analysis of Two Randomized Controlled Studies

INTRODUCTION: Patients are seeking greater involvement in their healthcare. It therefore may be beneficial to provide guidance on initial oral sumatriptan dose selection for the treatment of acute migraine in nontraditional settings, such as telehealth and other remote forms of medical care. We soug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fisher, Matt, Aher, Abhay, Araga, Mako, Franks, Billy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134697/ https://www.ncbi.nlm.nih.gov/pubmed/37103731 http://dx.doi.org/10.1007/s40122-023-00511-3

Ejemplares similares

Efficacy of Sumatriptan/Placebo versus Sumatriptan/Propofol Combination in Acute Migraine; a Randomized Clinical Trial
por: Farahmand Rad, Reza, et al.
Publicado: (2022)

Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache
por: Moore, Johanna C, et al.
Publicado: (2012)

Influence of sumatriptan on the autonomic system during migraine attacks
por: Dalla Volta, G., et al.
Publicado: (2006)

Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine
por: Assadpour, Sara, et al.
Publicado: (2022)

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment
por: Tfelt-Hansen, Peer
Publicado: (2007)

The Use of Neuroimaging for Predicting Sumatriptan Treatment Response in Patients With Migraine
por: Wu, Jr-Wei, et al.
Publicado: (2022)

Metoclopramide versus sumatriptan for treatment of migraine headache: A randomized clinical trial
por: Talabi, Saeid, et al.
Publicado: (2013)

Pharmacokinetics study of chitosan-coated liposomes containing sumatriptan in the treatment of migraine
por: Assadpour, Sara, et al.
Publicado: (2022)

Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients
por: Sternieri, E., et al.
Publicado: (2005)

Sumatriptan–naproxen fixed combination for acute treatment of migraine: a critical appraisal
por: Khoury, Chaouki K, et al.
Publicado: (2010)

Cilostazol induced migraine does not respond to sumatriptan in a double blind trial
por: Falkenberg, Katrine, et al.
Publicado: (2018)

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
por: Brand-Schieber, Elimor, et al.
Publicado: (2016)

Predicting Sumatriptan Responsiveness Based on Structural Connectivity in Patients Newly Diagnosed With Migraine
por: Lee, Dong Ah, et al.
Publicado: (2023)

Managing migraine headaches experienced by patients who self–report with menstrually related migraine: a prospective, placebo–controlled study with oral sumatriptan
por: Dowson, A. J., et al.
Publicado: (2005)

Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder
por: Obaidi, Mohammad, et al.
Publicado: (2013)

Sumatriptan (50 and 100 mg) in repeated migraine attacks: a patient preference study
por: Zanchin, Georgio, et al.
Publicado: (2000)

Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study
por: Sandrini, G, et al.
Publicado: (2007)

Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine
por: Cady, Roger K., et al.
Publicado: (2017)

Metabolism of sumatriptan revisited
por: Pöstges, Timo, et al.
Publicado: (2023)

Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans
por: Diamond, S., et al.
Publicado: (2007)

Investigation of the immunoreactivities of NOS enzymes and the effect of sumatriptan in adolescent rats using an experimental model of migraine
por: Kurul, Semra Hiz, et al.
Publicado: (2008)

The effect of intravenous administration of liposomal curcumin in addition to sumatriptan treatment in an experimental migraine model in rats
por: Bulboacă, Adriana E, et al.
Publicado: (2018)

AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
por: Tepper, Stewart J, et al.
Publicado: (2015)

Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine
por: Tepper, Stewart J, et al.
Publicado: (2018)

Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
por: Apelian, Rami, et al.
Publicado: (2022)

Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo‐controlled randomized clinical trials
por: Schim, Jack D., et al.
Publicado: (2022)

Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial
por: Rahimdel, Abolghasem, et al.
Publicado: (2014)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

Application of Design of Experiment for Polyox and Xanthan Gum Coated Floating Pulsatile Delivery of Sumatriptan Succinate in Migraine Treatment
por: Jagdale, Swati C., et al.
Publicado: (2014)

From investigational product to active reference: evolution of oral sumatriptan efficacy versus placebo for the treatment of acute migraine episodes and potential impact in comparative analyses
por: Thokagevistk, Katia, et al.
Publicado: (2019)

Treatment resistant trigeminal neuralgia relieved with oral sumatriptan: a case report
por: Moran, JA, et al.
Publicado: (2009)

Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
por: Shibata, Mamoru, et al.
Publicado: (2023)

Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine
por: Vikelis, Michail, et al.
Publicado: (2012)

Post hoc Bayesian model selection
por: Friston, Karl, et al.
Publicado: (2011)

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
por: Pozo-Rosich, Patricia, et al.
Publicado: (2021)

Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine‐Associated Nausea and Prior Triptan Use on Efficacy
por: Lipton, Richard B., et al.
Publicado: (2017)

Spontaneous splenic infarction associated with sumatriptan use
por: Arora, A., et al.
Publicado: (2006)

Bilateral Renal Infarctions During the Use of Sumatriptan
por: Abramovitz, Blaise, et al.
Publicado: (2018)

Functional Hybrid Nanoemulsions for Sumatriptan Intranasal Delivery
por: Ribeiro, Lígia N. M., et al.
Publicado: (2020)

Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
por: Doty, Erin Gautier, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gehrgkh3ffoo9j5fhghhukb9is